Rate Video

BTOG 2020 | Mesothelioma trials update: CONFIRM, BEAT-meso & MARS2

Sanjay Popat • 31 Jan 2020

Lung Cancer Mesothelioma Atezolizumab Bevacizumab Carboplatin Nivolumab Pemetrexed

BEAT-meso CONFIRM MARS2 PROMISE-meso Immuno-Oncology

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the various trials on mesothelioma. Prof. Popat highlights the CONFIRM (NCT03063450), BEAT-meso (NCT03762018) and MARS2 (NCT02040272) trial. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

DS-8201 + pembro in patients HER2+ breast and NSCLC

Sanjay Popat • 11 Jun 2020

CALGB 140503: sub-lobar resection non-inferior to lobectomy in stage IA node-negative NSCLC

Sanjay Popat • 8 Aug 2022

CheckMate 153 trial: how long should nivolumab be taken for?

Sanjay Popat • 8 Sep 2017

CheckMate 227 update

Sanjay Popat • 29 Sep 2019

Related Videos

Building a clinical research platform to capture and leverage data from cancer care in Germany

Frank Griesinger

Improving responses to immunotherapy in NSCLC

How to discuss immunotherapy as a treatment option with lung cancer patients

Clinical factors in the selection of patients for first-line immunotherapy of lung cancer